Andrew Goetz

1.7k total citations
20 papers, 1.4k citations indexed

About

Andrew Goetz is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Andrew Goetz has authored 20 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 9 papers in Oncology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Andrew Goetz's work include Cancer Treatment and Pharmacology (6 papers), Cancer therapeutics and mechanisms (6 papers) and Neutropenia and Cancer Infections (4 papers). Andrew Goetz is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Cancer therapeutics and mechanisms (6 papers) and Neutropenia and Cancer Infections (4 papers). Andrew Goetz collaborates with scholars based in United States, France and Germany. Andrew Goetz's co-authors include Eric K. Rowinsky, Amita Patnaik, Anthony W. Tolcher, Chris H. Takimoto, Garry Schwartz, Lisa A. Hammond, Bahram Forouzesh, Leonel Ochoa, Louis Denis and Alain C. Mita and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Andrew Goetz

20 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew Goetz United States	13	480	465	408	246	192	20	1.4k
Jinee Rizzo United States	16	645 1.3×	652 1.4×	1.2k 2.9×	195 0.8×	177 0.9×	26	1.8k
Jun Ho Yi South Korea	22	214 0.4×	514 1.1×	552 1.4×	100 0.4×	324 1.7×	88	1.5k
Debra H. Josephs United Kingdom	26	282 0.6×	679 1.5×	704 1.7×	144 0.6×	127 0.7×	79	2.1k
Alejandra Perez United States	12	611 1.3×	493 1.1×	842 2.1×	96 0.4×	588 3.1×	30	1.6k
Joanne Halsey United States	19	298 0.6×	667 1.4×	1.1k 2.7×	98 0.4×	145 0.8×	32	1.7k
Jean Bauer Switzerland	22	582 1.2×	378 0.8×	1.2k 2.9×	118 0.5×	447 2.3×	52	1.8k
Sagun Parakh Australia	19	306 0.6×	389 0.8×	892 2.2×	129 0.5×	79 0.4×	79	1.5k
Raffaele Longo Italy	19	297 0.6×	567 1.2×	571 1.4×	79 0.3×	326 1.7×	64	1.5k
G. Dark United Kingdom	14	334 0.7×	558 1.2×	476 1.2×	37 0.2×	265 1.4×	28	1.4k
Christopher A. Slapak United States	23	247 0.5×	1.1k 2.5×	1.3k 3.1×	273 1.1×	251 1.3×	42	2.3k

Countries citing papers authored by Andrew Goetz

Since Specialization

Citations

This map shows the geographic impact of Andrew Goetz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Goetz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Goetz more than expected).

Fields of papers citing papers by Andrew Goetz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Goetz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Goetz. The network helps show where Andrew Goetz may publish in the future.

Co-authorship network of co-authors of Andrew Goetz

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Goetz. A scholar is included among the top collaborators of Andrew Goetz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Goetz. Andrew Goetz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Padgett, Clifford W., et al.. (2024). Comparison of N···I and N···O Halogen Bonds in Organoiodine Cocrystals of Heterocyclic Aromatic Diazine Mono-N-oxides. Crystal Growth & Design. 24(6). 2425–2438. 3 indexed citations

2.

Goetz, Andrew, et al.. (2016). Crystal structure of (E)-2-[(2-bromopyridin-3-yl)methylidene]-6-methoxy-3,4-dihydronaphthalen-1(2H)-one and 3-[(E)-(6-methoxy-1-oxo-1,2,3,4-tetrahydronaphthalen-2-ylidene)methyl]pyridin-2(1H)-one. Acta Crystallographica Section E Crystallographic Communications. 72(7). 955–958. 2 indexed citations

3.

Mita, Alain C., Louis Denis, Eric K. Rowinsky, et al.. (2009). Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors. Clinical Cancer Research. 15(2). 723–730. 260 indexed citations

4.

Takimoto, Chris H., Martin A. Graham, G. Lockwood, et al.. (2007). Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function. Clinical Cancer Research. 13(16). 4832–4839. 56 indexed citations

5.

Kubitz, Jens C., et al.. (2006). The influence of positive end-expiratory pressure on stroke volume variation and central blood volume during open and closed chest conditions. European Journal of Cardio-Thoracic Surgery. 30(1). 90–95. 43 indexed citations

6.

Mita, Alain C., Christopher J. Sweeney, Sharyn D. Baker, et al.. (2006). Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function. Journal of Clinical Oncology. 24(4). 552–562. 90 indexed citations

7.

Calvo, Emiliano, Andrew Goetz, Peter L. Bonate, et al.. (2005). Analysis of dose proportionality testing methods in phase I clinical trials of anticancer agents. Cancer Research. 65. 973–974. 1 indexed citations

8.

Goetz, David W., Bonnie A. Whisman, & Andrew Goetz. (2005). Cross-reactivity among edible nuts: double immunodiffusion, crossed immunoelectrophoresis, and human specific IgE serologic surveys. Annals of Allergy Asthma & Immunology. 95(1). 45–52. 75 indexed citations

9.

Posey, James, Muhammad Wasif Saif, Andrew Goetz, et al.. (2005). Phase 1 Study of Weekly Polyethylene Glycol-Camptothecin in Patients with Advanced Solid Tumors and Lymphomas. Clinical Cancer Research. 11(21). 7866–7871. 40 indexed citations

10.

Ricart, Alejandro D., Lisa A. Hammond, John G. Kuhn, et al.. (2005). Phase I and Pharmacokinetic Study of Sequences of the Rebeccamycin Analogue NSC 655649 and Cisplatin in Patients with Advanced Solid Tumors. Clinical Cancer Research. 11(24). 8728–8736. 9 indexed citations

11.

Calvo, Emiliano, Eric K. Rowinsky, A. W. Tolcher, et al.. (2004). A phase I and pharmacokinetic study of rubitecan, an orally administered topoisomerase I (topo-I) inhibitor, combined with gemcitabine in patients with advanced cancer. Journal of Clinical Oncology. 22(14_suppl). 2099–2099. 2 indexed citations

12.

Calvo, Emiliano, Eric K. Rowinsky, A. W. Tolcher, et al.. (2004). A phase I and pharmacokinetic study of rubitecan, an orally administered topoisomerase I (topo-I) inhibitor, combined with gemcitabine in patients with advanced cancer. Journal of Clinical Oncology. 22(14_suppl). 2099–2099. 1 indexed citations

13.

Tolcher, Anthony W., Stanton L. Gerson, Denis Lairon, et al.. (2003). Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. British Journal of Cancer. 88(7). 1004–1011. 285 indexed citations

14.

Hao, Desirée, Lisa A. Hammond, Sabine Eckhardt, et al.. (2003). A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor.. PubMed. 9(7). 2465–71. 36 indexed citations

15.

Patnaik, Amita, S. Gail Eckhardt, Elżbieta Izbicka, et al.. (2003). A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.. PubMed. 9(13). 4761–71. 29 indexed citations

16.

Forouzesh, Bahram, Chris H. Takimoto, Andrew Goetz, et al.. (2003). A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.. PubMed. 9(15). 5540–9. 12 indexed citations

17.

Takimoto, Chris H., Scot C. Remick, Sunil Sharma, et al.. (2003). Dose-Escalating and Pharmacological Study of Oxaliplatin in Adult Cancer Patients With Impaired Renal Function: A National Cancer Institute Organ Dysfunction Working Group Study. Journal of Clinical Oncology. 21(14). 2664–2672. 95 indexed citations

18.

Takimoto, Chris H., Kira Glover-Cutter, Xiaoke Huang, et al.. (2003). Phase I pharmacokinetic and pharmacodynamic analysis of unconjugated soy isoflavones administered to individuals with cancer.. PubMed. 12(11 Pt 1). 1213–21. 111 indexed citations

19.

Patnaik, Amita, Eric K. Rowinsky, Miguel A. Villalona, et al.. (2002). A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies.. PubMed. 8(7). 2142–8. 112 indexed citations

20.

Rowinsky, Eric K., Jinee Rizzo, Leonel Ochoa, et al.. (2002). A Phase I and Pharmacokinetic Study of Pegylated Camptothecin as a 1-Hour Infusion Every 3 Weeks in Patients With Advanced Solid Malignancies. Journal of Clinical Oncology. 21(1). 148–157. 96 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact